



## Aliqopa™ (copanlisib)

Last Review Date: May 1<sup>st</sup>, 2018

Number: MG.MM.PH.46v2

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definitions

Aliqopa (copanlisib): is a kinase inhibitor of phosphatidylinositol-3-kinase (PI3K) and works primarily through isoforms PI3K-alpha and PI3K-beta which are expressed in malignant B cells. The result may be tumor cell death via apoptosis and inhibition of proliferation of primary malignant B cell lines. Several important cell-signaling pathways are also inhibited by copanlisib, such as CXCR12 mediated chemotaxis of malignant B cells, B-cell receptor (BCR) signaling and NF-kappa-B signaling in lymphoma cell lines.

### Dosing

Max Units (per dose and over time):

- 60 mg Days 1, 8, & 15 of a 28-day cycle

### Guideline

Aliqopa (copanlisib) may be considered medically necessary when all of the following criteria are met:

- Patient is 18 years of age or older; **AND**
- Patient has a diagnosis of relapsed follicular lymphoma (FL); **AND**
- Aliqopa (copanlisib) is being used as a single-agent; **AND**
- Patient has failed at least two prior therapies.

Coverage for Aliqopa (copanlisib) may be renewed when the following criteria are met:

- Disease response; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following:  $\geq$  Grade 3 infections, uncontrolled hyperglycemia, uncontrolled hypertension, non-infectious pneumonitis, ANC  $<$  0.5 x 10<sup>3</sup> cells/mm<sup>3</sup>, severe cutaneous reactions, etc.

### Limitations/Exclusions

- Approval will be granted for 6 months, and may be renewed

### Revisions

12/3/2018 – Added J9057 and removed J9999, C9399 from Applicable Procedure Codes.

### Applicable Procedure Codes

J9057	Injection, copanlisib, 1mg
-------	----------------------------

### Applicable Diagnosis Codes

C82.00	Follicular lymphoma grade I, unspecified site
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes
C82.07	Follicular lymphoma grade I, spleen
C82.08	Follicular lymphoma grade I, lymph nodes of multiple site
C82.09	Follicular lymphoma grade I, extanodal and solid organ sites
C82.10	Follicular lymphoma grade II, unspecified site
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes
C82.17	Follicular lymphoma grade II, spleen
C82.18	Follicular lymphoma grade II, lymph nodes of multiple site
C82.19	Follicular lymphoma grade II, extanodal and solid organ sites
C82.20	Follicular lymphoma grade III, unspecified site
C82.21	Follicular lymphoma grade III, lymph nodes of head, face, and neck
C82.22	Follicular lymphoma grade III, intrathoracic lymph nodes
C82.23	Follicular lymphoma grade III, intra-abdominal lymph nodes
C82.24	Follicular lymphoma grade III, lymph nodes of axilla and upper limb
C82.25	Follicular lymphoma grade III, lymph nodes of inguinal region and lower limb
C82.26	Follicular lymphoma grade III, intrapelvic lymph nodes
C82.27	Follicular lymphoma grade III, spleen
C82.28	Follicular lymphoma grade III, lymph nodes of multiple site

C82.29	Follicular lymphoma grade III, extanodal and solid organ sites
C82.30	Follicular lymphoma grade IIIa, unspecified site
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes
C82.37	Follicular lymphoma grade IIIa, spleen
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple site
C82.39	Follicular lymphoma grade IIIa, extanodal and solid organ sites
C82.40	Follicular lymphoma grade IIIb, unspecified site
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes
C82.47	Follicular lymphoma grade IIIb, spleen
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple site
C82.49	Follicular lymphoma grade IIIb, extanodal and solid organ sites
C82.80	Other types of follicular lymphoma, unspecified site
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes
C82.87	Other types of follicular lymphoma, spleen
C82.88	Other types of follicular lymphoma, lymph nodes of multiple site
C82.89	Other types of follicular lymphoma, extanodal and solid organ sites
C82.90	Follicular lymphoma, unspecified, unspecified site
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes
C82.97	Follicular lymphoma, unspecified, spleen
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple site
C82.99	Follicular lymphoma, unspecified, extanodal and solid organ sites

## References

1. Aliqopa PI prescribing information. Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 2017.
2. Clinical Pharmacology Elsevier Gold Standard. 2017.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2017.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2017.

5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2017